Form 4: Acadia Pharmaceuticals Executive Exercises Stock Options and Sells Shares to Cover Taxes

An Acadia Pharmaceuticals executive, Brendan Teehan, exercised stock options and sold shares to cover tax obligations, according to a recent SEC Form 4 filing.

Summary

• Brendan Teehan, an executive at Acadia Pharmaceuticals, engaged in transactions involving the company's stock.
• On November 17, 2024, Teehan acquired 9,913 shares of common stock through the exercise of restricted stock units.
• Also on November 17, 2024, Teehan acquired an additional 9,913 shares of common stock through the exercise of restricted stock units.
• On November 19, 2024, Teehan sold 10,329 shares of common stock at a weighted average price of $16.81 per share.
• These sales were made to cover withholding taxes and tax-related items associated with the vesting of restricted stock units.
• Following these transactions, Teehan directly owns 62,105 shares of Acadia Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions, which are neither positive nor negative for the company's overall outlook. It's a neutral event.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• The vesting schedule of the restricted stock units, with 37.5% vesting after 18 months and the remainder over the following three years, is a fairly standard practice in the pharmaceutical industry.
• The sale of shares to cover tax obligations is also a common practice among executives who receive equity compensation.
• Companies like Biogen and Amgen also have similar vesting schedules and insider trading policies.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and do not indicate a change in the company's fundamentals.

Key Dates

Keywords

Acadia Pharmaceuticals, stock options, restricted stock units, SEC Form 4, insider trading, executive compensation, stock sale, Brendan Teehan